Jyong Biotech Ltd. (MENS)

$10.11 -4.89 (-32.60%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,440,831
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New...

Industry: Biotechnology
Sector: Healthcare
Phone: 886 2 2732 5205
Address:
No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan
GrowthCapitall
GrowthCapitall Jul. 2 at 3:50 PM
$MENS showcasing its botanical drug portfolio at BIO 2026. Still a niche biotech name, but the setup is about pipeline visibility and investor attention rather than headlines. Market will likely care more about follow-through than the event itself.
0 · Reply
RAMMFANN
RAMMFANN Jun. 29 at 9:02 PM
$MENS Anyone think 67+ is possible?
0 · Reply
Calafk
Calafk Jun. 26 at 1:39 PM
$MENS we are going🚀👍
0 · Reply
kshonstocks
kshonstocks Jun. 24 at 4:16 PM
$MENS thru 9 dma w abv avg volume for it
0 · Reply
aquira
aquira Jun. 17 at 12:25 AM
$MENS been stagnant for 6 months. What a waste of time and money. Could've made money somewhere else
1 · Reply
Everythingisplanned
Everythingisplanned Jun. 16 at 6:22 AM
$MENS Let this day be the day to remember!!
0 · Reply
Noriudar
Noriudar Jun. 12 at 3:27 PM
$MENS hey Mens! Waiting for good news! Wake up!
1 · Reply
Everythingisplanned
Everythingisplanned Jun. 11 at 6:05 PM
$MENS Finally some volume!! Lets go!
0 · Reply
Noriudar
Noriudar Jun. 11 at 4:55 PM
$MENS around 3 tonight
1 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 3:53 PM
$MENS Outstanding article that hits the mark on MENS's current state. So if you want to refresh your MENS insights or learn about MENS from scratch, this is a must read. https://everyticker.com/quote/MENS/analysis/mens-a-clinical-stage-biotech-running-out-of-runway-amid-legal-storms-and-api-uncertainty-nasdaq-mens
1 · Reply
Latest News on MENS
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Jul 2, 2026, 8:00 AM EDT - 2 days ago

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

May 15, 2026, 8:30 AM EDT - 7 weeks ago

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech Annual report: Q4 2025

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Jyong Biotech Annual report: Q4 2025

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Mar 27, 2026, 8:30 AM EDT - 3 months ago

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong issues strategic corporate update, completes Phase II trial for MCS-8

2026-02-12T13:35:22.000Z - 5 months ago

Jyong issues strategic corporate update, completes Phase II trial for MCS-8

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Feb 12, 2026, 8:30 AM EST - 5 months ago

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech subsidiary announces phase II data for MCS-8

2026-01-30T13:45:59.000Z - 5 months ago

Jyong Biotech subsidiary announces phase II data for MCS-8

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jan 30, 2026, 8:30 AM EST - 5 months ago

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech ‘not aware’ of any material information amid share price movement

2025-12-19T14:05:13.000Z - 7 months ago

Jyong Biotech ‘not aware’ of any material information amid share price movement

Jyong Biotech Responds to Share Price and Volume Movement

Dec 19, 2025, 9:00 AM EST - 7 months ago

Jyong Biotech Responds to Share Price and Volume Movement

Jyong Biotech Ltd trading resumes

2025-12-17T16:30:17.000Z - 7 months ago

Jyong Biotech Ltd trading resumes

Jyong Biotech Ltd trading halted, volatility trading pause

2025-12-17T16:20:33.000Z - 7 months ago

Jyong Biotech Ltd trading halted, volatility trading pause

Jyong Biotech signs MOU with Vietnam pharmaceutical distributor

2025-12-04T13:40:52.000Z - 7 months ago

Jyong Biotech signs MOU with Vietnam pharmaceutical distributor

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Dec 4, 2025, 8:30 AM EST - 7 months ago

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Jyong Biotech signs non-binding LOI with South Korean pharma company

2025-11-24T13:45:25.000Z - 7 months ago

Jyong Biotech signs non-binding LOI with South Korean pharma company

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Nov 24, 2025, 8:30 AM EST - 7 months ago

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8

2025-11-20T13:45:58.000Z - 8 months ago

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Nov 20, 2025, 8:30 AM EST - 8 months ago

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Sep 29, 2025, 8:30 AM EDT - 9 months ago

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Jyong Biotech Ltd trading halted, volatility trading pause

2025-09-19T20:00:42.000Z - 10 months ago

Jyong Biotech Ltd trading halted, volatility trading pause

Jyong Biotech Ltd trading resumes

2025-09-19T20:00:15.000Z - 10 months ago

Jyong Biotech Ltd trading resumes

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Sep 18, 2025, 8:30 AM EDT - 10 months ago

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Jyong Biotech completes patient enrollment in Phase II trial of MCS-8

2025-09-16T12:26:29.000Z - 10 months ago

Jyong Biotech completes patient enrollment in Phase II trial of MCS-8

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Sep 16, 2025, 8:18 AM EDT - 10 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8

2025-08-22T13:05:15.000Z - 11 months ago

Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Aug 22, 2025, 9:00 AM EDT - 11 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jyong Biotech Ltd trading resumes

2025-08-11T14:05:39.000Z - 11 months ago

Jyong Biotech Ltd trading resumes

Jyong Biotech Ltd trading halted, volatility trading pause

2025-08-11T13:50:46.000Z - 11 months ago

Jyong Biotech Ltd trading halted, volatility trading pause

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jul 22, 2025, 10:40 AM EDT - 1 year ago

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jun 18, 2025, 5:20 PM EDT - 1 year ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Jun 16, 2025, 11:38 PM EDT - 1 year ago

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

GrowthCapitall
GrowthCapitall Jul. 2 at 3:50 PM
$MENS showcasing its botanical drug portfolio at BIO 2026. Still a niche biotech name, but the setup is about pipeline visibility and investor attention rather than headlines. Market will likely care more about follow-through than the event itself.
0 · Reply
RAMMFANN
RAMMFANN Jun. 29 at 9:02 PM
$MENS Anyone think 67+ is possible?
0 · Reply
Calafk
Calafk Jun. 26 at 1:39 PM
$MENS we are going🚀👍
0 · Reply
kshonstocks
kshonstocks Jun. 24 at 4:16 PM
$MENS thru 9 dma w abv avg volume for it
0 · Reply
aquira
aquira Jun. 17 at 12:25 AM
$MENS been stagnant for 6 months. What a waste of time and money. Could've made money somewhere else
1 · Reply
Everythingisplanned
Everythingisplanned Jun. 16 at 6:22 AM
$MENS Let this day be the day to remember!!
0 · Reply
Noriudar
Noriudar Jun. 12 at 3:27 PM
$MENS hey Mens! Waiting for good news! Wake up!
1 · Reply
Everythingisplanned
Everythingisplanned Jun. 11 at 6:05 PM
$MENS Finally some volume!! Lets go!
0 · Reply
Noriudar
Noriudar Jun. 11 at 4:55 PM
$MENS around 3 tonight
1 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 3:53 PM
$MENS Outstanding article that hits the mark on MENS's current state. So if you want to refresh your MENS insights or learn about MENS from scratch, this is a must read. https://everyticker.com/quote/MENS/analysis/mens-a-clinical-stage-biotech-running-out-of-runway-amid-legal-storms-and-api-uncertainty-nasdaq-mens
1 · Reply
Everythingisplanned
Everythingisplanned Jun. 10 at 2:13 PM
$MENS
0 · Reply
aquira
aquira Jun. 9 at 3:59 PM
$MENS looks very dead
0 · Reply
Everythingisplanned
Everythingisplanned Jun. 1 at 12:16 PM
$MENS https://pharmaboardroom.com/interviews/fu-feng-kuo-founder-ceo-jyong-biotech/
1 · Reply
Everythingisplanned
Everythingisplanned May. 29 at 3:12 AM
$MENS
0 · Reply
Mario19860
Mario19860 May. 24 at 11:35 AM
$MENS some new news?
0 · Reply
Everythingisplanned
Everythingisplanned May. 21 at 6:58 PM
$MENS
0 · Reply
DavidMichery12345
DavidMichery12345 May. 11 at 7:01 AM
$MENS Bought $1,000 shares at $60. HOLD 🤟
2 · Reply
aquira
aquira May. 5 at 2:57 PM
$MENS this turd is really testing my payyytience. Foooken helll
0 · Reply
Everythingisplanned
Everythingisplanned Apr. 29 at 4:32 AM
$MENS https://finance.yahoo.com/sectors/healthcare/articles/jyong-biotech-updates-market-access-000000493.html
1 · Reply
aquira
aquira Apr. 21 at 8:02 PM
$MENS i fucking knew it. 6 consecutive red days down from high of 3.05 a week ago. Fooken hell. Looks like it's going back to 1.6-1.8. Fuck this crap. All gains in 2 months erased in just 6 days. Fooken hell
0 · Reply
aquira
aquira Apr. 21 at 3:37 PM
$MENS next time it goes up to 2.8, i'm gonna fuckung pull out and invest again at 2.10-2.15
0 · Reply
aquira
aquira Apr. 20 at 2:27 PM
$MENS this has been falling for 5 days now. Wtfffff
0 · Reply